The global artificial pancreas device systems market accounted for USD 0.401 billion in 2023 and is expected to reach USD 2.72 billion by 2034 with a CAGR of 19.02% during the forecast period 2024-2034. The rising prevalence of diabetes, technological advancements, increased R&D, increased demand for automated glycemic control systems, government support and funding, and strategic collaborations and partnerships will drive market expansion.
Medical device manufacturers are continually developing and investing extensively in research and development (R&D) to produce more sophisticated, user-friendly, and effective APDSs. These developments, like as enhanced sensor technology, better insulin delivery algorithms, and interconnectivity with other diabetic devices, are making APDSs more appealing to patients and healthcare providers. For instance, Medtronic announced in December 2023 the release of the InPenTM smart insulin pen, which is coupled with the GuardianTM Connect CGM and allows diabetics to make data-driven decisions about insulin dosage.
By device type, the threshold-suspended device systems segment accounted for the highest revenue-grossing segment in the global artificial pancreas device systems market in 2023 owing to the high demand for advanced hypoglycemia prevention features and enhanced patient safety measures. For instance, Tandem Diabetes Care announced in January 2024 that the FDA had cleared its t: slim X2TM insulin pump with Control-IQTM advanced hybrid closed-loop technology for children six years of age and up. Additionally, the control-to-range (CTR) Systems segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of personalized and flexible insulin delivery options, coupled with advancements in control algorithms for better glucose management.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global artificial pancreas device systems market in 2023 owing to the growing preference for professional supervision, access to specialized care, and integration of artificial pancreas systems into clinical practice guidelines. For instance, Insulet Corporation announced in November 2023 that it would acquire Canè SpA, a major producer of insulin pump infusion sets. Additionally, the home care settings segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on patient empowerment, remote monitoring capabilities, and the convenience of managing diabetes in familiar environments.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of diabetes, robust healthcare infrastructure, favorable reimbursement policies, and early adoption of advanced medical technologies. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the growing number of people living with diabetes, improving healthcare infrastructure, rising disposable income, and growing awareness. For instance, Dexcom announced in February 2024 that the FDA had cleared its Dexcom G7® CGM System, a small, wearable, disposable diabetes sensor.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Medical device manufacturers are continually developing and investing extensively in research and development (R&D) to produce more sophisticated, user-friendly, and effective APDSs. These developments, like as enhanced sensor technology, better insulin delivery algorithms, and interconnectivity with other diabetic devices, are making APDSs more appealing to patients and healthcare providers. For instance, Medtronic announced in December 2023 the release of the InPenTM smart insulin pen, which is coupled with the GuardianTM Connect CGM and allows diabetics to make data-driven decisions about insulin dosage.
By device type, the threshold-suspended device systems segment accounted for the highest revenue-grossing segment in the global artificial pancreas device systems market in 2023 owing to the high demand for advanced hypoglycemia prevention features and enhanced patient safety measures. For instance, Tandem Diabetes Care announced in January 2024 that the FDA had cleared its t: slim X2TM insulin pump with Control-IQTM advanced hybrid closed-loop technology for children six years of age and up. Additionally, the control-to-range (CTR) Systems segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of personalized and flexible insulin delivery options, coupled with advancements in control algorithms for better glucose management.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global artificial pancreas device systems market in 2023 owing to the growing preference for professional supervision, access to specialized care, and integration of artificial pancreas systems into clinical practice guidelines. For instance, Insulet Corporation announced in November 2023 that it would acquire Canè SpA, a major producer of insulin pump infusion sets. Additionally, the home care settings segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on patient empowerment, remote monitoring capabilities, and the convenience of managing diabetes in familiar environments.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of diabetes, robust healthcare infrastructure, favorable reimbursement policies, and early adoption of advanced medical technologies. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the growing number of people living with diabetes, improving healthcare infrastructure, rising disposable income, and growing awareness. For instance, Dexcom announced in February 2024 that the FDA had cleared its Dexcom G7® CGM System, a small, wearable, disposable diabetes sensor.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Device Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Artificial Pancreas Device Systems Market Report 2023 - 2034
Artificial Pancreas Device Systems Market Analysis & Forecast by Device Type 2023 - 2034 (Revenue USD Bn)
- Threshold Suspend Device Systems
- Control-to-Range (CTR) Systems
- Control-to-Target (CTT) Systems
Artificial Pancreas Device Systems Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Clinics
- Homecare settings
Artificial Pancreas Device Systems Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Artificial Pancreas Device Systems Market: Device Type Estimates & Trend Analysis
8. Artificial Pancreas Device Systems Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Artificial Pancreas Device Systems Market
11. Europe Global Artificial Pancreas Device Systems Market
12. Asia Pacific Global Artificial Pancreas Device Systems Market
13. Latin America Global Artificial Pancreas Device Systems Market
14. MEA Global Artificial Pancreas Device Systems Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Medtronic plc
- Tandem Diabetes Care Inc.
- Insulet Corporation
- Dexcom Inc.
- Abbott Laboratories
- Beta Bionics Inc.
- Bigfoot Biomedical
- Cellnovo Group SA
- TypeZero Technologies LLC
- Diabeloop SA
- Beta-O2 Technologies Ltd.
- Admetsys Corporation
- Defymed
- Inreda Diabetic BV
- Pancreum LLC.
